MAP3K7 and chronic myelomonocytic leukemia: Similar to our findings (Fig. 7), the expression levels of ABCB7 and MAP3K7 were significantly lower in SF3B1MUT-MDS patients than in SF3B1WT-MDS patients, which was also confirmed for the cohort excluding CMML (Chronic myelomonocytic leukemia) and RAEB (Refractory anemia with excess blasts) (see Supplementary Fig. S28 online).